Cipher Pharma (CPHR) Tops Q4 EPS by 8c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/8/2026
- Wall St slips as climbing oil, yields amplify inflation fears
- Oil jumps as Middle East supply concerns persist amid shipping attacks
- Chipotle, Starbucks shares volatile after report of potential takeover
- Why Citi says the Fed could be setting up for a dovish surprise
- Alphabet shares rise as Google pushes Gemini deeper into enterprise AI
- Anthropic launches Claude Haiku 5.5 with tiered pricing structure
- Sportradar to sell Synergy Sports coaching unit for $170M
- Rezolve AI (RZLV) Reiterated at Overweight by Cantor Fitzgerald on Positioning as Key Component in E-Commerce Stack
- Wall Street ends lower, off record highs, as Treasury yields climb
- CoreWeave stock drops on dilution fears and debt concerns
Cipher Pharmaceuticals Reports 2015 Financial Results
February 24, 2016 7:07 AM ESTQ4 revenue up 30%, Company significantly advances strategic plans to build adermatology growth company
MISSISSAUGA, ON, Feb. 24, 2016 /PRNewswire/ - Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX: CPH) ("Cipher" or "the Company") today announced its financial and operational results for the three and twelve months ended December 31, 2015.
"In 2015 we made major strides to transform Cipher from a royalty business into an integrated dermatology growth company with a solid commercial foundation in the U.S. and Canada, a portfolio of currently marketed products, and a robust pipeline of... More



